Cat. No. | Product name | CAS No. |
DC10149 |
TM5275 sodium salt
Featured
TM5275 is an orally available, potent and selective inhibitor of PAI-1 that delivers antithrombotic benefits devoid of bleeding effect in nonhuman primates. |
1103926-82-4 |
DC10374 |
TM5441
Featured
TM5441 is a novel orrally active TAP-1 antagonist. |
1190221-43-2 |
DC10083 |
UK-371804
Featured
UK-371804 is a potent and selective uPA inhibitor with excellent enzyme potency (Ki 10 nM) and selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin). |
256477-09-5 |
DC12039 |
ZK824859
Featured
ZK824859 is a selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. |
2254001-81-3 |
DC11078 |
Cenupatide
Featured
Cenupatide is an urokinase plasminogen activator receptor (uPAR) inhibitor drug candidate. Cenupatide inhibits uPAR binding to the formyl peptide receptors (FPRs) can improve kidney lesions in a rat model of streptozotocin (STZ)-induced diabetes. Cenupatide was found to revert STZ-induced up-regulation of uPA levels and activity, while uPAR on podocytes and (s)uPAR were unaffected. In glomeruli, Cenupatide inhibited FPR2 expression suggesting that the drug may act downstream uPAR, and recovered the increased activity of the αvβ3 integrin/Rac-1 pathway indicating a major role of uPAR in regulating podocyte function. |
1006388-38-0 |
DC42471 |
Angstrom6
Angstrom6 (A6 Peptide) is an 8 amino-acid peptide derived from single-chain urokinase plasminogen activator (scuPA) and interferes with the uPA/uPAR cascade and abrogates downstream effects. Angstrom6 binds to CD44 resulting in the inhibition of migration, invasion, and metastasis of tumor cells, and the modulation of CD44-mediated cell signaling. |
220334-14-5 |